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Drug-Eluting Stent Restenosis
A Need for New Technology?*
John S. Douglas JR, MD
tlanta, Georgia
In this 35th year of percutaneous coronary intervention, reste-
nosis after stent implantation remains a significant limitation,
resulting in increased costs and morbidity, reduced quality of
life, and in some patients, a need for surgical coronary revas-
cularization. Drug-eluting stents (DES) proved superior to
bare-metal stents (BMS) in preventing restenosis, but as
increasingly complex lesions were treated, drug-eluting stent–
in-stent restenosis (DES-ISR) exceeded the single digit rates
initially reported for simple lesions (1,2). Some seek solace in
the observation that DES-ISR is more frequently focal, due
perhaps to the potent anti-proliferative drug effects as well as
mechanical factors, such as focal stent under-expansion, stent
fracture, loss of longitudinal integrity, and/or incomplete stent
apposition (3–5). Although bare-metal stent–in-stent resteno-
sis (BMS-ISR) lesions have been shown to respond favorably
to balloon dilation, especially when focal, and significantly
better after DES implantation in a randomized trial (6),
See page 728
there is increasing evidence that even focal DES-ISR is a
more resistant lesion that is associated with high subsequent
major adverse cardiac events after percutaneous retreatment
(7–9). Optimal therapy of DES-ISR is essential to avoid a
third symptomatic or ischemic presentation that might
signal a need for surgery, especially in the presence of left
main or left anterior descending coronary artery lesions.
Observational studies have shown that the extent of the
DES-ISR lesion determines the outcome of percutaneous
therapy. Restenosis occurred in 29% of focal (10 mm)
lesions, 46% of diffuse (10 mm) lesions, and 66% of total
occlusions among 481 consecutive de novo DES-ISR le-
sions during a median follow-up of 3 years (2). Major
adverse cardiac events were reported in one-third of patients
with DES-ISR, irrespective of lesion type (2). Observa-
tional studies have provided evidence that DES are more
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the contents of this paper to disclose.effective than simple balloon angioplasty for treatment of
diffuse as well as focal DES-ISR lesions, but this compar-
ison has not been evaluated in prospective randomized trials
(1,2). In this issue of JACC: Cardiovascular Interventions,
Alfonso et al. (10) in a prospective observational trial
attempt to assess the value of treating a DES-ISR lesion
with a different DES, compared with alternative strategies
(balloon dilation, BMS, or the same DES). This report is
the third in a series of studies by this group analyzing
treatment strategies for stent restenosis. It has the advantage
of being performed by experienced investigators in a net-
work of participating centers.
The RIBS-III (Restenosis Intra-Stent: Balloon Angio-
plasty Versus Drug-Eluting Stent) was a prospective, ob-
servational study that analyzed outcomes of 363 patients
with DES-ISR treated in 12 Spanish university hospitals.
The recommended strategy of implanting a different DES
was carried out in 274 patients (75%), and the remaining 89
patients (25%) were treated at the discretion of the operator
with balloon angioplasty (n 29, 33%), BMS (n 9, 10%),
or the same DES that was initially implanted (n  51,
57%). Follow-up angiography was performed in 275 of 355
(77%) eligible patients at a median of 278 days. The main
angiographic endpoint was in-segment minimal lumen
diameter (MLD) at 9-month follow-up as assessed by
quantitative coronary angiography in a core laboratory. The
main clinical outcome was a composite of cardiac death,
myocardial infarction, and target lesion revascularization at
1 year. Angiographic evaluation at 9 months revealed a
larger MLD in patients receiving a different DES, com-
pared with 89 patients treated with alternative strategies
(1.86 vs. 1.40 mm, p  0.003), and recurrent restenosis was
less (22% vs. 40%, p  0.008). The combined primary
clinical endpoint occurred less frequently in the different DES
group (23% vs. 35%, p 0.039), because of less target lesion
evascularization. The rate of definite/probable stent throm-
osis was low and similar in both groups (0.7% vs. 1.1%).
ropensity score analysis was used in an attempt to correct
or baseline differences. What does this study tell us? Simply
tated, in an observational study patients with DES-ISR
esions fared better with a different DES than a group of
atients treated with either balloon dilation, BMS, or the
ame DES. As always, comparisons of treatment effective-
ess in an observational study are risky, due to potential
nknown and unmeasured confounders. For a number of
easons, the findings reported should be no surprise.
Although the reference vessel diameter in the 2 groups of
atients was similar (2.41 mm vs. 2.46 mm, p  0.45), the
LD achieved after treatment of the DES-ISR lesions was
ignificantly smaller in the “other strategy” group (2.08 mm
s. 2.26 mm, p  0.007). This parallels the findings in the
ISAR-DESIRE 2 (Intracoronary Stenting and Angio-
graphic Results: Drug Eluting Stents for In-Stent Resteno-
sis 2) randomized comparison of balloon angioplasty versus
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739DES for BMS-ISR where the MLD achieved acutely with
balloon angioplasty was significantly smaller than with implan-
tation of 2 different DES (2.07 mm vs. 2.52 mm and 2.56 mm,
p 0.001) (6). Although this might represent a form of elastic
recoil or tissue prolapse, an additional component of stent
under-expansion cannot be excluded, because intravascular
imaging was used in 40% of patients in the RIBS-III study.
The authors reported significantly better acute and 9-month
angiographic results when imaging was used, suggesting
under-expansion might have existed in unimaged patients.
The late lumen loss reported in the “other strategy” group
was significantly greater than in the group of patients
treated with a different DES (0.63 vs. 0.42 mm, p  0.02).
The magnitude of the late loss in the “other strategy” was
similar to that reported after balloon angioplasty of BMS-
ISR in the RIBS-II study of 0.69 mm (11) and that reported
after balloon angioplasty of sirolimus-eluting stent (SES)-
ISR by Habara et al. (12) of 0.72 mm. The late loss of 0.42
mm reported for the “switch” group is similar to that
reported by Mehilli et al. (13) in the ISAR-DESIRE 2
study when SES-ISR lesions were treated with either SES
or paclitaxel-eluting stent (0.38 and 0.40 mm, respectively).
The 9-month angiographic follow-up interval that was
chosen would be expected to capture most restenoses after
balloon angioplasty or BMS implantation, but persistence of
in-stent lumen loss beyond this time frame after DES
implantation is known to occur and would not be detected.
The authors make note of a “low but persistent event rate
beyond the first year.”
The 4 types of DES implanted in this study have differing
antirestenotic effects, with everolimus- and sirolimus-eluting
stents displaying increased potency in most (1) but not all
studies (13). The choice of DES was operator-determined.
The authors report in this study that patients receiving limus-
DES or second-generation DES had less restenosis. However,
the distribution of limus–DES and second-generation DES
between the 2 treatment groups was not provided.
Pharmacotherapy was not the same for the 2 groups of
patients. Dual antiplatelet therapy for 1 year was given to
patients with repeat DES implantation, but the 43% of
“alternative strategy” patients treated with balloon angioplasty
or BMS received dual antiplatelet therapy for 1 month.
This report is 1 of several observational studies indicating
that implantation of a DES to treat DES-ISR was safe and
associated with better long-term outcomes, primarily reduced
recurrences, when compared with alternative strategies, which
included balloon angioplasty (1,14,15). However, a random-
ized controlled trial comparing these treatments has not been
performed. The authors report that this study is the sixth
observational trial in which a switch in DES strategy has been
analyzed. Most report similar outcomes, whether DES were
changed or the same. In the only randomized controlled trial,
Mehilli et al. (13) reported outcomes of 450 patients with
SES-ISR randomized to receive paclitaxel-eluting stent orSES. There were no differences in late lumen loss, restenosis,
target lesion revascularization, safety outcomes, or stent throm-
bosis. Should one infer that the absence of the usual SES
superiority in a patient with SES failure indicates drug resis-
tance? Perhaps, but more data are needed to determine
whether a different, the same, or simply the most potent DES
is the best current treatment for DES-ISR.
Randomized trials comparing the efficacy of potent
second-generation DES, the promising new and largely
untested drug-eluting balloons, bioresorbable drug-eluting
scaffolds, and conventional balloon angioplasty will be
required to establish optimal therapy for this resistant new
“disease,” DES-ISR. A breakthrough technology is sorely
needed to treat this malady or prevent its occurrence.
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